Reported Sunday, Hemab Therapeutics Presents New HMB-002 Clinical Data Showing ≥2.4-Fold Dose-Dependent VWF And FVIII Increases In Von Willebrand Disease, Introduces HMB-003 For Heavy Menstrual Bleeding At ISTH 2026 Congress

Loading news article.

Reported Sunday, Hemab Therapeutics Presents New HMB-002 Clinical Data Showing ≥2.4-Fold Dose-Dependent VWF And FVIII Increases In Von Willebrand Disease, Introduces HMB-003 For Heavy Menstrual Bleeding At ISTH 2026 Congress | WAPE

Reported Sunday, Hemab Therapeutics Presents New HMB-002 Clinical Data Showing ≥2.4-Fold Dose-Dependent VWF And FVIII Increases In Von Willebrand Disease, Introduces HMB-003 For Heavy Menstrual Bleeding At ISTH 2026 Congress

Article summary

Related companies

Comments —